Tourmaline Bio, Inc.
TRML · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | -$0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $67 | $32 | $18 | $0 |
| G&A Expenses | $23 | $13 | $2 | $0 |
| SG&A Expenses | $23 | $13 | $2 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $47 |
| Operating Expenses | $90 | $45 | $20 | $47 |
| Operating Income | -$90 | -$45 | -$20 | -$48 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $17 | $3 | $0 | -$0 |
| Pre-Tax Income | -$73 | -$42 | -$20 | -$48 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$73 | -$42 | -$20 | -$0 |
| % Margin | – | – | – | – |
| EPS | -2.89 | -8.87 | -0.97 | -0 |
| % Growth | 67.4% | -814.4% | -969,900% | – |
| EPS Diluted | -2.89 | -8.87 | -0.97 | -0 |
| Weighted Avg Shares Out | 25 | 5 | 20 | 11 |
| Weighted Avg Shares Out Dil | 25 | 5 | 20 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $3 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$17 | $0 | $0 | $1 |
| EBITDA | -$90 | -$42 | -$20 | -$47 |
| % Margin | – | – | – | – |